Search

Your search keyword '"Nikitin, Eugene"' showing total 257 results

Search Constraints

Start Over You searched for: Author "Nikitin, Eugene" Remove constraint Author: "Nikitin, Eugene"
257 results on '"Nikitin, Eugene"'

Search Results

1. Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias

5. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

8. Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.

14. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

18. S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.

19. Significant reduction in the incidence of non‐coronavirus infections in patients with chronic lymphocytic leukemia on ibrutinib and venetoclax treatment during the COVID‐19 pandemic: An additional benefit of lockdown

20. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

26. Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia

27. Ibrutinib in combination with rituximab is highly effective in treatment of steroid refractory autoimmune hemolytic anemia

30. Multiple myeloma: response to treatment and survival of patients according to the interim analysis of the Russian observational, retrospective-prospective, multicenter cohort study (MULTISPECT)

31. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome

32. CLL-186 Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia

33. Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia

36. COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study

38. Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia.

39. Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

40. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial

45. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia:a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

48. CLL-088: Neutropenia Analysis of Venetoclax Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Pooled Data from VENICE-I and -II Phase 3b Trials

49. Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.

Catalog

Books, media, physical & digital resources